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I. INTRODUCTION
Nearly one percent of over 850 DNA samples from Eastern
European Jews contained a specific gene mutation that may
predispose them to breast and ovarian cancer, according to
study results published today in Nature Genetics.'
This finding offers the first evidence from a large study that an
alteration in the gene, called breast cancer I (BRCA1), is pres-
ent at measurable levels not only in families at high risk for the
disease, but in a specific group of the general population.2
With the publication of today's results, the National Institutes
of Health (NIH) also announced its plans to launch a series of
clinical studies to evaluate cancer risk in Eastern European, or
Ashkenazi, Jews bearing the mutation. The results of these
studies will help determine whether BRCA1 testing should be
offered to the nation's six million Ashkenazi Jews as a part of
their health care.3
IT WAS THIS NIH PRESS RELEASE dated September
28, 1995, and the press conference that followed, that would
first alert and alarm the Jewish community. The BRCA1 gene
had been isolated a year earlier and numerous unique mutations
had been detected in the germline of individuals with breast
and ovarian cancer.4 About five to ten percent of all breast
1. Scientists Report New Lead in the Genetics of Breast Cancer, NIH NEWS (Nat'l Inst. of
Health, U.S. Dept. of Health & Hum. Serv., Washington, D.C.), Sept. 28, 1995, at 1 (citing Jeffrey
P. Struewing et al., The Carrier Frequency of the BRCA1 185delAG Mutation is Approximately )
Percent in Ashkenazi Jewish Individuals, 11 NATURE GENETICS 198, 198 (1995)).
2. Id. at 1.
3. Id. at 1.
4. See Jeffrey P. Struewing et al., The Carrier Frequency of the BRCAI 185delAG Muta-
tion is Approximately I Percent in Ashkenazi Jewish Individuals, 11 NATURE GENETIS 198, 199
(noting that data has been derived almost exclusively from families with a wide range of
mutations ascertained on the basis of a high incidence of breast and ovarian cancer, and that it is
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cancers appear to be inherited and a significant proportion were
related to the BRCA1 gene.' In high-risk families, female car-
riers of BRCA1 mutations were estimated to have an eighty-
five percent lifetime risk of breast cancer and a forty percent
risk of ovarian cancer.' Because current mutation detection is
very difficult, it has not been feasible to analyze large numbers
of samples, but the 185delAG mutation had been detected rela-
tively frequently.7 Of the ten published families with this mu-
tation, it was discovered that all were Ashkenazi Jews.8 Thus,
this association between a specific mutation and a genetic
subpopulation prompted the scientists to target the Jewish
population for further genetics research on the prevalence of
the BRCA1 mutation.9
A follow-up population study tested eight hundred fifty-
eight stored DNA samples taken from Ashkenazi individu-
als.' These samples had originally been collected for Tay-
Sachs and Cystic Fibrosis screening in the United States and
Israel, and thus, were not chosen for the presence of breast
cancer or positive family history for cancer." All individual
identifiers were removed from the samples prior to analysis. 2
Eight of the samples were carriers for the 185delAG, whereas
none of the eight hundred fifteen samples in the control group
(not selected for ethnic origin) tested positive. 3 Thus, about
one percent (0.9%) of the Jewish samples carry this mutation,
apparently derived from a common ancestor. 4 This is a sur-
prisingly high frequency, making this mutation "potentially the
possible that the penetrance will be lower in unselected patients).
5. Id.
6. Id.
7. Id.
8. Id. It was subsequently reported that over twenty Jewish families with breast or ovarian
cancer had been identified with the 185delAG. See Francis S. Collins, BRCA1 -- Lots ofMutations,
Lots of Dilemmas, 334 NEw ENG. J. MED. 186, 186 (1996) (presenting issues related to BRCAI
testing including pros and cons of testing individuals).
9. It has also been reported by U.S. and French researchers that at least 3 in 1,000
Ashkenazi Jews might carry one particular alteration in BRCA2. Rita Rubin, Would I Gain by
Being Tested? No, U.S. NEws & WORLD REP., May 13, 1996, at 77.
10. See Struewing et al., supra note 4, at 198 (explaining the methods and results of the
genetic sample study).
11. See id.
12. See id.
13. See id.
14. See id.
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most common serious single-gene disease yet identified in any
population group."'5 It is estimated that this rate of alteration
is three 6 to eight 7 times higher than all BRCA1 alterations
combined in the general population.
The NIH researchers conceded that "[w]hile the finding
raises the possibility of testing, it does not provide any data on
precise cancer risk."'8 Scientists still do not know to what
extent having the altered gene increases a woman's risk of de-
veloping breast or ovarian cancer. Nor do they know to what
extent it might increase the risk for colon or prostate cancer in
men. Thus, NIH scientists, with the support of Jewish commu-
nity leaders, conducted a follow-up study on blood samples of
over five thousand men and women from the Ashkenazi Jewish
population in the Washington, D.C. area. The purposes of the
study were: "1) to learn how common the 185delAG alteration
is, and 2) to see if people with this alteration have more rela-
tives with cancer."' 9 The study did not involve testing for can-
cer and study participants did not receive test results. In addi-
tion to a blood sample, participants filled out a questionnaire
about family history of cancer and information about ancestry.
Jewish leaders actively encouraged people to participate and
many synagogues and Jewish community centers served as
sites for the study. "In history, Jews have bled for negative rea-
sons,"20 and this was an opportunity for Jews to give blood to
help their people, said Rabbi Matthew Simon, the president of
the UJA Federation of Greater Washington.2' Within less than
two months, between February and April, 1996, NIH and the
Jewish organizations had recruited over five thousand Jews in
the Washington, D.C. area for participation in this study.
15. Collins, supra note 8, at 186.
16. See The 185delAG Alteration in BRCAI: What does this Mean for Jewish Women,
FACT SHEET (Nat'l. Inst. of Health, U.S. Dep't. of Health & Hum. Serv., Washington, D.C.),
1995, at 5.
17. See Collins, supra note 8, at 186.
18. See Nat'l Inst. of Health, supra note 1, at 1 (quoting Dr. Jeffrey Struewing, scientist
with the National Cancer Institute and the National Center for Human Genome Research).
19. Nat'l Inst. of Health, Familial Cancer and the BRCAI Gene in the Jewish Community
of Greater Washington (1996) (informed consent form from NIH research study) (on file with
author).
20. Doctors Launch New Jewish Cancer Test: Amid Fear and Confusion, Search Facts Be-
gins, FORWARD, Mar. 1, 1996, at 5 [hereinafter Doctors Launch New Jewish Cancer Test].
21. Id.
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Even though the study results are yet to be reported, tar-
geting Jews for testing is growing in both the research commu-
nity and in the commercial market. Numerous studies are now
in place to test Jewish women for the 185delAG in BRCA1
mutation.' For example, four thousand Ashkenazi women with
recently diagnosed breast cancer are being recruited from seven
metropolitan New York City hospitals. Participants in this
study will receive results and will be followed for four
years.' Even though the essential research on precise cancer
risks has not been completed, commercial laboratories are also
targeting Jews for testing. The Genetics and In-Vitro Fertiliza-
tion (IVF) Institute in Fairfax, Virginia advertises on the
Internet that it will offer population screening to Ashkenazi
Jews for the 185delAG mutation, even though "[t]here are
many questions ... that still need to be answered in careful
clinical studies."24 The Jewish Week, a popular Jewish news-
paper, suggests that if you want more information on the
185delAG test, "have your doctor contact The Genetics and
IVF Institute."'  Currently, the cost of the test is $295.26 The
Genetics and IVF Institute also advertises that it will test for a
few additional mutations in Jewish families, but cannot yet
offer such testing to non-Jews, "since no other mutations have
yet been identified that are specific for a particular ethnic or
racial group.,''
22. See generally Nancy J. Nelson, A Burst of Research Activity Follows BRCAI Finding,
88 J. NAT'L CANCER INST. 230, 230 (1996) (describing several genetic studies initiated in the
aftermath of the discovery of the BRCA1 gene). The Fox Chase Cancer Center in Philadelphia,
Pa., was testing for the 185delAG deletion in several hundred Ashkenazi women, both affected
and unaffected. Id. at 231. The Women's College Hospital in Toronto is testing for the
185delAG deletion in 200 to 300 Jewish women with ovarian cancer. Id. The University of Utah,
Salt Lake City and Memorial Sloan-Kettering Cancer Center in New York have tested for the
185delAG deletion in young Jewish women with breast cancer or in families with one or two
affected first-degree relatives. Id.
23. Id.at230-31.
24. See Genetics & IVF Institute, Breast andlor Ovarian Cancer Risk in Jewish Women:
Role of the l85delAG and other Mutations in the BRCAI and BRCA2 Genes (visited Aug. 25,
1996) (http://www.givf.com/brcal.html) (describing the role of mutations in the BRCA1 and
BRCA2 genes and promoting genetic screening for Ashkenazi Jews as a specifically affected
group).
25. Diana Willensky, Optimism in Breast Cancer Fight, JEWISH WEEK, Mar. 8, 1996, at 45.
26. See Ridgely Ochs, Genetic Findings on Breast CancerlThe Door's Open, Researchers
Say, But the Landscape Remains Murky, NEWSDAY, May 14, 1996, at B23 (describing recent
findings related to BRCA1 and options for testing).
27. Genetics & IVF Institute, supra note 24.
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Most recently, the Hartford Jewish Ledger began printing
on a regular basis an advertisement entitled, "An Important
Message -- Genetic Testing for Breast Cancer in Jewish Wom-
en," by Kenneth A. Kern, M.D.' Dr. Kern first states that
"[s]everal recent cancer studies have confirmed that Jewish
women of Ashkenazi (Eastern European) heritage carry dam-
aged genes that lead to breast cancer more commonly than the
non-Jewish population."29  Relying on numerous statistics he
declares as fact: "if you carry damaged breast cancer genes
and you live long enough, you are almost guaranteed to de-
velop breast cancer."3 Dr. Kern then offers to provide genet-
ic testing "by a blood test"'" in his office. He concludes that
"the decision to undergo testing requires thought, counseling,
and courage."32  Obviously, the research agenda has fueled
the marketing strategy for the commercialization of predictive
genetic testing for breast cancer.
H. GENETIC TESTING IN CONTEXT:
EMERGING THEMES
A. Genetic Myopia, the Genetic "Quick-Fix," and the
Genetic Underclass
Before the ethical, legal, and social challenges embedded
in predictive genetic testing for breast cancer in Jewish women
can be addressed, it must first be placed more generally in the
context of developing genetic technologies in our society.
Three themes emerge which will be briefly explored: genetic
myopia; genetic testing as a "quick fix"; and the genetic
underclass. Genetic myopia is a condition that results from
viewing everything from the perspective of genetics. As a
result, genetic reductionism and genetic determinism develop in
28. Kenneth A. Kern, An Important Message -- Genetic Testing for Breast Cancer in
Jewish Women, HARTFORD JEWISH LEDGER, Nov. 22, 1996, at 13 (advertising that Dr. Kern spe-
cializes in "Diseases of the Breast and Tumor Surgery').
29. Id.
30. Id.
31. Id.
32. Id. (emphasis added).
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our society.33 Genetic reductionism results when all traits,
health problems, and behaviors become attributable to genes
and no attention is paid to other potential factors. Thus, if a
gene for cancer is found in an individual, other factors, such as
environmental toxins, lifestyle, and diet, will be dismissed as
not contributing to the development of the disorder. In a relat-
ed way, genetic determinism results when an individual be-
lieves her future is defined and predicted by genetic makeup
and cannot be changed. People may not be motivated to adopt
a healthy lifestyle if they believe that their fate is predeter-
mined genetically and therefore, that they cannot prevent dis-
ease by reducing other risk factors such as smoking cigarettes.
Such attitudes may have significant negative implications for
public health and prevention messages. Genetic myopia may, in
fact, seriously undermine cancer surveillance and prevention
strategies aimed at the population at large.
The genetic "quick fix" theme views genetic testing as an
end in and of itself, rather than as a means toward an end that
is yet to be defined. By trying to perfect the predictive test,
have we failed to concurrently think through what to do once
the test result is available? What is the value of the informa-
tion, its benefits and risks to individuals and their families, its
impact on health behavior, and the role of providers in advis-
ing about the implications and limitations of test results?
The "genetic underclass" theme describes a future popula-
tion unable to gain access to genetic testing in the United
States. At present, we live in a society where over forty million
people have no health insurance and limited or no access to
our health care system.34 Without access to health care, it is
unlikely that these individuals would have access to genetic
testing or related services. How will resources be allocated to
33. See, e.g., Abby Lippman, Prenatal Genetic Testing and Screening: Constructing Needs
and Reinforcing Inequities, 17 AM. J. L. & MED. 15, 17-18 (1991) (exploring the consequences of
prenatal genetic testing and screening on women and their health care needs); Dorothy Nelkin,
The Grandiose Claims of Geneticists, CHRON. HIGHER EDUC., Mar. 3, 1991, at BI (suggesting
that the rhetoric used by geneticists could foster genetic determinism and be used to justify
discrimination).
34. See Sources of Health Insurance and Characteristics of the Uninsured: Analysis of the
March 1994 Current Population Survey, SPECIAL REPORT AND ISSUE BRIEF No. 158 (Employee
Benefit Research Institute, Washington, D.C.), Feb. 1995, at 1, 4 (providing summary data on the
insured and uninsured as well as discussing changes in health protection).
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make sure that in the future, the economic underclass does not
also become the genetic underclass?
B. Genetic Accountability and Genetic Identity
Two additional themes emerge in the context of testing for
inherited breast cancer in the Jewish community: genetic ac-
countability and genetic identity. These themes are not unique
to Jewish women, but provide a useful paradigm for further
analysis and for placing genetic testing in context. Historically,
pregnant women have been the main targets of genetic testing,
and mothers serve as the primary caretakers of those born with
genetic disorders. Genetic accountability results when women
are deemed responsible for seeking genetic information."
Women may believe they have a duty to give birth to the per-
fect baby free of genetic abnormalities. The expansion of ge-
netic testing may give the impression that we can and should
take complete control and responsibility for the results of birth.
Although many pregnant women may feel this sense of genetic
accountability, certain ethnic groups, including Jewish women,
have historically been targeted for testing. Historically, Jewish
women have accepted that it is their responsibility to be tested
for their carrier status for Tay-Sachs, a "Jewish" genetic dis-
ease.36 Indeed, the Orthodox Jewish community has estab-
lished a counseling and testing program for couples prior to
being matched for marriage,37 called Dor Yeshorim, that pro-
motes carrier testing for Tay-Sachs and a few other genetic
disorders more common among Jews. Testing, however, is only
done for recessive genetic disorders which require two carriers
for there to be a risk to future offspring. Dor Yeshorim's edu-
cational materials include a reprint of a letter from a mother
who did not have her daughter tested before the daughter mar-
35. See generally R. Alta Charo & Karen H. Rothenberg, "The Good Mother": The Limits
of Reproductive Accountability and Genetic Choice, in WOMEN AND PRENATAL TESTING: FACING
THE CHALLENGES OF GENETIC TECHNOLOGY 105 (Karen H. Rothenberg & Elizabeth J. Thomson
eds., 1994) (discussing the issues surrounding reproductive genetic testing and responses to the
increased responsibilities it may create).
36. See generally id.
37. See COMMISSION FOR PREVENTION OF JEWISH GENETIC DISEASES, DOR YESHORIM,
AVOID A TERRIBLE TRAGEDY FOR YOU AND YOUR CHILDREN! (1996).
104 [Vol. 7:97
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fled. The daughter subsequently gave birth to a child with Tay-
Sachs.38 The mother writes: "I am guilty, no one but I am
guilty of their present tragic state."39 Thus, genetic account-
ability in both the preconceptual and the prenatal context has
been part of the Jewish culture for many years.
Genetic accountability and genetic identity are now ex-
panding beyond prenatal testing. Jewish women may perceive a
"social obligation to do anything they [can] to advance"' re-
search on BRCA1 testing. Accordingly, at least one researcher
has warned that "those obtaining consent for Jewish women
[for BRCA1 testing] should be aware of the 'slippery slope'
from perceived social responsibility to coercion."'" Further-
more, Jewish women feel particularly responsible for seeking
information about genetic predisposition to breast cancer, in
part for the "sake of one's children."'42 As noted earlier, much
of the attention in research, the commercial market place, and
the media over the last year has been on the "Jewish genes"
for breast cancer. Newspaper headlines sum it all up: "Doctors
Launch New Jewish Cancer Test"43 and "Doc Wants New
Study of Jewish Cancer Gene."' For Jews, a genetic identity
to familial cancer is being legitimized by our drive for the
genetic "quick fix."
I. ETIFUCAL AND LEGAL IMPLICATIONS Of
INFORMED CONSENT
With these themes in context, the ethical and legal issues
can become more focused. The first issue, with both ethical
and legal implications, is informed consent. The informed
consent model for genetic (and HIV) testing has altered the
traditional paradigm. Rather than focusing on the medical risks
38. A Letter Received by Dor Yeshorim with the Request to Publicize it to the Community
(Dor Yeshorim trans.) (Dor Yeshorim, Washington, D.C.) 1995.
39. Id.
40. Gail Geller et al., Informed Consent and BRCA1 Testing, 11 NATURE GENETICS 364,
364(1995).
41. Id.
42. Id.
43. Doctors Launch New Jewish Cancer Test, supra note 20, at 5.
44. Doc Wants New Study of Jewish Cancer Gene: Is Screening Warranted?, FORWARD,
Feb. 9, 1996, at 6 [hereinafter Doc Wants New Study of Jewish Cancer Gene] (calling for a study
to see whether screening and prevention are necessary).
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associated with the procedure, which are minimal, the emphasis
is on disclosure of the psychological and societal risks for the
individual and family receiving the information. 5 It is impor-
tant to note, however, that it is very difficult to have a mean-
ingful informed consent process when we still know so very
little about the relative risks and benefits of genetic testing.
A number of assumptions have been made about the bene-
fits of predictive testing and the value of predictive informa-
tion. It has been argued that test results will relieve uncertain-
ty; promote early detection, surveillance, prevention, and inter-
vention strategies; enable us to better plan for the future; influ-
ence reproductive decision making; and give us information to
share with blood relatives (particularly children), so that they
can better assess their risk for cancer.
On the other hand, assumptions are made about the risks
as well. These are not the traditional risks associated with an
invasive, medical intervention. Rather, as noted earlier, they are
social and psychological risks that typically have not been the
major focus of the informed consent process. It has been ar-
gued that genetic information will increase anxiety; change
self-image; alter family relationships; create social and group
stigma; impact on privacy and confidentiality; and result in
both insurance and employment discrimination.
In fact, we must question the assumptions about both
benefits and risks. The reality is that we have very little data.
First of all, the value of this predictive information is unknown
and it will remain unknown for the near future. Further, it is
important to emphasize that whereas genetic information may
be predictive, it is not, in and of itself, a definitive diagnosis.
Additionally, it is difficult for individuals to evaluate both
predictive information and relative risks and how those relate
within the context of their lives.' Finally, these predictive
tests are not perfect and may never be for all population
groups. How can such limitations be translated, if at all, for the
45. See generally OFFICE FOR PROTECTION FROM RESEARCH RISKS, U.S. DEPT. OF HEALTH
& HUM. SERV., PROTECTING HUMAN RESEARCH SUBJECTS, INSTITUTIONAL REVIEW BOARD
GUIDEBOOK 5-42 to 5-63 (1993) (addressing ethical issues raised by human genetic research).
46. See Elizabeth J. Thomson, Communicating Complex Genetic Information, in GENES
AND HUMAN SELF-KNOWLEDGE 172 (R.F. Weir et al. eds., 1994).
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individual not trained in genetics or risk assessment? How
good, in fact, does the genetic information have to be in order
to benefit individuals as members of society? In light of the
above, it becomes critical for the health care provider to be
skilled in risk assessment in order to determine who best can
potentially benefit from genetic testing. Thus, the evolving
standard of care should not be focused on the provider's duty
to offer testing, per se, but rather on the quality of risk assess-
ment and the appropriateness of testing.
Accordingly, we must also question the assumptions made.
about predictive testing and its potential for a positive impact
on cancer surveillance and prevention strategies. What, in fact,
do we currently know about baseline health promotion and
disease prevention behaviors? Based on what we know about
cancer prevention and interventions, what assumptions are
reasonable to make with respect to adherence, change of be-
havior, and access to these strategies in our current health care
system? Furthermore, what should people with a positive test
be advised? Should they be told to obtain mammograms more
often or less often? Should women with BRCA1 mutations be
offered chemoprevention and/or prophylactic mastectomies as
prevention strategies?47 Should men with mutations be offered
prophylactic prostatectomy? How can we counsel about the
benefits and risks of surgical options without any long-term
data on the impact of such interventions? We need to formulate
a risk/benefit analysis to determine whether the benefits of
predictive testing for cancer outweigh the risks with respect to
both medical and psychological well-being.
IV. GENETIC INFORMATION AND HEALTH
INSURANCE
One societal risk at issue is the discrimination that may
result in the health insurance setting.' Researchers report that
47. See Struewing et al., supra note 4, at 198. See also Yoshio Miki et al., A Strong
Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCAI, 266 SCIENCE 66, 66
(1994) (discussing the identification of the BRCA1 gene and how it will facilitate early diagnosis
of breast and ovarian cancer susceptibility).
48. See Karen H. Rothenberg, Genetic Information and Health Insurance: State Legislative
Approaches, 23 J. LAW MED. & ETHICs 312, 312 (1995) (detailing state approaches to the
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individuals considering enrollment in clinical genetic studies
fear that if genetic information is disclosed to third parties,
individuals and their families may face discrimination.49 Until
a few years ago, it was rare for legislation to address genetic
information in the health insurance context. In the 1970s, North
Carolina and Florida passed legislation prohibiting health insur-
ers from refusing to issue insurance or charging higher premi-
ums based on the sickle cell trait. In 1986, Maryland passed
legislation (since amended) that covered a number of traits
including Tay-Sachs, although insurers could continue to use
genetic information to discriminate if there was "actuarial
justification."'5
With the advent of the Human Genome Project, a new
generation of state legislation began to evolve with the pas-
sage, in 1991, of a Wisconsin law prohibiting health insurers
from:
• requiring or requesting an individual or a member of the
individual's family to obtain a genetic test;
• requiring or requesting directly or indirectly the results of a
genetic test;
- conditioning the provision of insurance coverage or benefits
on genetic testing; or
* considering genetic testing in the determination of rates.5
This approach attempts to integrate protection against
discrimination in insurance practices, coverage, benefits, and
rates with some privacy protection for the individual and
his/her family. Similar approaches have been incorporated to
varying degrees in recent legislation passed in California,52
problem of discrimination by insurance carriers based on genetic information); Kathy L. Hudson
et al., Genetic Discrimination and Health Insurance: An Urgent Need for Reform, 270 SciENcE
391, 391 (1995) (focusing on proposed reforms to protect consumers from health insurance
discrimination based on genetic information). See generally Ruth R. Faden & Nancy E. Kass,
Genetic Screening Technology: Ethical Issues in Access to Tests by Employers and Health
Insurance Companies, J. Soc. IssuEs, 1993, at 75, 83; Paul R. Billings et al., Discrimination as a
Consequence of Genetic Testing, 50 AM. J. HuM. GENETIcs 476, 476 (1992).
49. See Nat'l Inst. of Health, NIH-Funded Cancer Genetics Studies Consortium Meeting,
Nov. 2, 1995.
50. See Rothenberg, supra note 48, at 313.
51. Wis. STAT. ANN. § 631.89(2)(a)-(d) (1994).
52. CAL. INS. CODE §§ 10123.2, 10123.3, 10123.31, 10123.35, 10140, 10140.1,1 0140.5,
10147, 10148, 10149, 10149.1, 11512.95, 11512.96, 11512.965 (Deering 1996); CAL. HEALTH &
SAFETY CODE § 1374.7, 1374.9 (West 1994 & West 1995); S.B. 1740, 1995-96 Reg. Sess. (Cal.
1996) (enacted).
108 [Vol. 7:97
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Colorado,53  Georgia,54  Maryland,55  Minnesota,56  New
Hampshire,5 7  Ohio, 8  Oregon,59  Virginia,' and New Jer-
sey.6' Just within the last year, more than a dozen state leg-
islatures have considered bills addressing genetic discrimination
in health insurance.62
The development of public policy to address genetic infor-
mation and health insurance must be analyzed in the context of
a complex and inadequate health insurance system, the uncer-
tainty about the future scope and impact of genetic testing and
the political realities of a pluralistic society. The current patch-
work of state legislation does not provide a comprehensive
solution to genetic discrimination and health insurance. State
laws focus narrowly on genetic tests, rather than more broadly
on genetic information generated by family history, physical
examination, or the medical record. Although insurers are
prohibited from using the results of a chemical test of DNA, or
the protein product of a gene, they can still use other pheno-
type indicators, patterns of inheritance of genetic characteris-
tics, or requests for genetic testing as the basis for discrimina-
tion." Thus, "[m]eaningful protection against genetic discrimi-
nation requires that insurers be prohibited from using all infor-
mation about genes, gene products, or inherited characteristics
to deny or limit health insurance coverage."'
Further, the federal Employee Retirement Income Security
Act (ERISA) exempts self-funded plans from state insurance
53. COLO. REv. STAT. § 10-3-1104.7 (1996).
54. GA. CODE ANN. § 33-54-1-4 (1996).
55. MD. AN. CODE Art. 48a, § 223(a)(3) (1996).
56. MINN. STAT. § 72A.139(3) (1995).
57. N.H. REV. STAT. ANN. § 141-H:4 (1995).
58. OHIO REV. CODE ANN. §§ 1742.42, 1742.43, 3901.49, 3901.491, 3901.50, 3901.501
(Anderson 1996).
59. S.B. 276,68th Or. Leg. Assoc., Reg. Sess. (1995)(enacted).
60. VA. CODE ANN. § 38.2-508.4 (Michie 1996).
61. S.B. 695 & 854,207th Leg., 1st Ann. Sess. (N.J. 1996) (enacted).
62. See, e.g., H.B. 5705, 1996 Gen. Assembly Reg. Sess. (Conn. 1996) (prohibiting dis-
crimination based on an individual's genetic information in both employment and insurance
contexts); H.B. 1200, 109th Leg., 2d Reg. Sess. (Ind. 1996) (prohibiting health insurers from
discriminating on the basis of genetic information); H.B. 2943, 89th Gen. Assembly (Il. 1996)
(amending various state acts to prohibit the use of DNA information as a basis for certain in-
surability decisions).
63. See Hudson et al., supra note 48, at 392.
64. Id.
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laws. Nationwide, more than one-third of the non-elderly in-
sured obtain health insurance through self-funded plans.65 This
percentage is expected to increase as more and more employers
use self-funded plans to provide health insurance benefits in
the future. This Act preempts state law and therefore prevents
a statewide approach to regulating the use of genetic informa-
tion by all plans providing health benefits.'
With these policy considerations in mind, the following
recommendations were developed by the Working Group on
Ethical, Legal, and Social Implications of the Human Genome
Project (ELSI)67 and the National Action Plan on Breast Can-
cer (NAPBC)" for both state and federal policymakers to pro-
tect against genetic discrimination:69
1. Insurance providers should be prohibited from using genetic
information, or an individual's request for genetic services, to
deny or limit any coverage or establish eligibility, continuation,
enrollment, or contribution requirements.
2. Insurance providers should be prohibited from establishing
differential rates or premium payments based on genetic infor-
mation or an individual's request for genetic services.
3. Insurance providers should be prohibited from requesting or
requiring collection or disclosure of genetic information.
4. Insurance providers and other holders of genetic information
should be prohibited from releasing genetic information without
prior written authorization of the individual. Written authoriza-
tion should be required for each disclosure and include to
whom the disclosure would be made."0
The recommendations further provide that genetic infor-
mation be defined as "information about genes, gene products,
or inherited characteristics that may derive from the individual
65. Id.
66. Id.
67. The NIH-DOE ELSI Working Group has a "broad and diverse membership including
genome scientists; medical geneticists; experts in law, ethics, and philosophy; and consumers, to
explore and propose options for the development of sound professional and public policies related
to human genome research and its applications." Hudson et al., supra note 48, at 392-93.
68. The National Action Plan on Breast Cancer (NAPBC) is a "public-private partnership
designed to eradicate breast cancer as a threat to the lives of American women"; and NAPBC "has
identified genetic discrimination in health insurance as a high priority." Id. at 393.
69. These recommendations have been endorsed by the National Advisory Council on
Human Genome Research (NACHGR). Id.
70. Id.
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or a family member.",7' Insurance provider is defined as "an
insurance company, employer, or any other entity providing a
plan of health insurance or health benefits including group and
individual health plans whether fully insured or self-funded.
' 72
Based in part on the interest generated by these recom-
mendations and a growing awareness of the issues, particularly
among the breast cancer community and women's health advo-
cates, Congress has begun to take notice. The NAPBC/ELSI
recommendations have been incorporated in proposed legisla-
tion introduced by Representative Louise M. Slaughter73 and
Senators Diane Feinstein,74  Connie Mack,75  and Olympia J.
Snowe.7 6 Further, Senators Mark D. Hatfield 77 and Peter V.
Domenici78 and Representatives Clifford B. Steams79 and Jo-
seph P. Kennedy" have also introduced bills addressing ge-
netic discrimination in insurance and employment. Although
none of these genetic-specific proposals have passed, they have
influenced other health insurance legislation. The recently
enacted Health Insurance Portability and Accountability Act of
19961 specifically prohibits a group health insurance plan from
using "genetic information" to establish rules for eligibility or
continued eligibility. It also provides that genetic information
shall not be treated as a preexisting condition "in the absence
71. Id.
72. Id. Furthermore, legislation should provide enforcement mechanisms, including civil
and criminal liability to assure that insurance entities comply with these provisions. For example,
as noted earlier, California provides that negligent and willful disclosure of genetic test results
without authorization is subject to civil and criminal liability. CAL. INSUR. CODE §§ 10123.31,
10140.1, 10149.1, 11512.96 (Deering 1996).
73. H.R. 2748, 104th Cong. (proposing a bill entitled "Genetic Information Nondiscrimi-
nation in Health Insurance Act of 1995").
74. S. 1600, 104th Cong. (proposing a bill entitled the "Genetic Fairness Act of 1996").
75. Id.
76. S. 1694, 104th Cong. (proposing a bill entitled the "Genetic Information Nondis-
crimination in Health Insurance Act of 1996").
77. See S. 1416, 104th Cong. (1995) (proposing a bill entitled the "Genetic Privacy and
Nondiscrimination Act of 1996").
78. See S. 1898, 104th Cong. (1996) (proposing a bill entitled "Genetic Privacy and
Nondiscrimination Act of 1996").
79. See H.R. 2690, 104th Cong. (1995) (proposing a bill entitled "Genetic Privacy and
Nondiscrimination Act of 1995).
80. See H.R. 3477, 104th Cong. (1996) (proposing an amendment to the Fair Labor Stan-
dards Act of 1938 which would restrict employers in obtaining, disclosing, and using genetic
information).
81. See 104 Pub. L. No. 104-191, § 701, 110 Stat. 1936 (1996).
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of a diagnosis of the condition related to such information."82
Thus, a healthy woman who tests positive for a BRCA1 muta-
tion would not be deemed to have a pre-existing condition
related to breast cancer and this genetic information could not
be used in the determination of eligibility for a group insurance
plan, including self-funded plans. This is a significant first step
in the evolution of federal legislation. Genetic information,
although not defined in the legislation, is recognized broadly as
a "health-status-related factor" in need of specific protection."
Of course, this incremental approach to health care reform
does not provide the comprehensive protection outlined in the
NAPBC/ELSI recommendations. It does not prohibit insurers
from requiring or requesting genetic testing or requiring or
requesting the results of genetic testing. Thus, the burden is on
the individual to prove that the insurer used genetic informa-
tion to deny coverage or affect the terms and conditions of
insurance. It does not require insurers to obtain authorization
before disclosing genetic information. Nor does it prevent a
plan from increasing rates, excluding all coverage for a particu-
lar condition, or imposing lifetime caps on all benefits or on
specific benefits.84 Such applicable terms of a plan may have
a disparate impact on individual enrollees and may adversely
affect "individuals with serious illnesses."85 This form of dis-
crimination against women with breast cancer and/or a genetic
predisposition to breast cancer, for example, would be permit-
ted as long as plan characteristics are not "directed at individu-
al sick employees or dependents."86 Absent other contractual
and legal protections, plans could specifically exclude, for
example, prophylactic surgery. Of course, insurers might also
argue that surgery was not medically necessary, was experi-
mental, and/or was not a covered benefit since the insured had
only a predisposition to disease, but did not need treatment for
cancer.
87
82. Id. §701(b)(1)(B).
83. Id.
84. See H.R. REP. No. 104-736, at 406 (1996) (noting that a plan may impose restrictions
on coverage of conditions and benefits).
85. Jd. at 406.
86. Id. at 406-07.
87. See generally Katskee v. Blue Cross/Blue Shield, 515 N.W.2d 645 (Neb. 1994).
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The Act provides even less protection for those not in
group plans and provides no coverage for the uninsured. Thus,
even if the uninsured had access to genetic testing, the risk of
future insurance discrimination would be a reality. In addition,
the uninsured would not benefit from genetic information if
they could not afford to pay for the related prevention and
intervention strategies, including more frequent mammograms
and surgical interventions.
V. GENETIC INFORMATION AND THE
WORKPLACE
Genetic information in the workplace also poses societal
risks that impact on employment possibilities, health insurance,
and privacy. Following a conditional offer of employment,
employers can require a pre-employment medical exam which
may include a physical examination and blood tests (including
genetic tests). They may also require a general medical release
of an individual's medical records. Courts have held that em-
ployers have a legitimate interest in the mental and physical
condition of their employees if the conditions impact on one's
ability to perform the job, or are otherwise job-related.88 An
employer does not have to hire an employee who refuses to
provide a general medical release.89 Although an employer is
prohibited from discriminating based on a disability, it is diffi-
cult for the individual to prove that she did not get a job or
promotion, for example, based on her disability or other genet-
ic information."° There is no specific prohibition on the
employer's access to genetic information.9'
"Insured's breast-ovarian carcinoma syndrome was 'illness,' defined as 'bodily disorder' or
'disease,' within meaning of health insurance policy, notwithstanding insurer's contention that
syndrome was merely predisposition to cancer," and as such, prophylactic surgery for removal of
ovaries was covered. Id. at 645, 652.
88. See Mark A. Rothstein, Genetic Discrimination in Employment and the Americans with
Disabilities Act, 29 Hous. L. REv. 23, 38, 52-68 (1992) (noting that the only exception to the
ADA's prohibition on preemployment inquiries is that an employer may inquire into the
applicant's ability to perform job-related functions).
89. Id. at 63-64.
90. See id. at 52-68 (explaining the problems employees face when employers have access
to employee medical and genetic information).
91. See id. at 62-68 (describing ways in which the ADA allows employers to gain access to
their employee's genetic information).
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Employment opportunities and health insurance coverage
are clearly intertwined. The employer has a business interest in
hiring a healthy work force to limit health insurance claims. At
present, employers offering self-funded plans can alter benefits
to reduce or eliminate coverage for specific conditions or pro-
cedures. Although they cannot directly discriminate against an
individual, they could decide, for example, not to cover partic-
ular procedures that may affect certain groups of people more
than others. Since many employers directly review health in-
surance claims, as a practical matter, there is no assurance of
medical privacy in the workplace.
In order to protect against genetic discrimination in the
workplace, in 1995, the U.S. Equal Employment Opportunity
Commission issued a guidance in its compliance manual on the
definition of disability: the Americans with Disabilities Act
(ADA) would protect individuals subjected to discrimination on
the "basis of genetic information relating to illness, disease or
other disorders."92 To further clarify their position, they cite
as an example an individual with a positive predictive genetic
test for colon cancer as being subject to protection under the
ADA. However, this provision may not cover carriers of reces-
sive or X-linked disorders. To date, there have been no genetic
discrimination complaints filed with the EEOC and the guide-
lines have yet to be tested in court. There is no federal law that
specifically addresses the use, misuse, and access to genetic
information in the workplace, although a number of proposals
have recently been introduced. 93
Over the last few years, a number of states, including
Wisconsin,94  Rhode Island,95  Iowa, 96  New York,97  New
Hampshire,98  Oregon, 99  and New Jersey"°°  have passed
92. 2 EQUAL EMPLOYMENT OPPORTUNITY COMM'N, COMPLIANCE MANUAL, § 902, Order
915.002, 902-45 (1995).
93. See S. 1416, 104th Cong. (1995) (prohibiting discrimination by employers based on
genetic information); H.R. 2690, 104th Cong. (1995) (proposing the protection of genetic
information in the workplace); S. 1898, 104th Cong. § 301 (1996) (regulating the use of genetic
information by employers); H.R. 3477, 104th Cong. (1996) (limiting the use of genetic
information in determining preexisting conditions).
94. See Wis. STAT. ANN. § 111.372 (West 1996).
95. See R.I. GEN. LAWS § 28-6.7-1 (1995).
96. See IOWA CODE ANN. § 729.6 (West 1996).
97. See A.B. 7839,219th Gen. Assembly, 2d Reg. Sess. (N.Y. 1996) (enacted).
98. See N.H. REV. STAT. ANN. § 141-H:3 (1995).
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legislation that, to varying degrees, prohibits genetic testing as
a condition of employment; prohibits genetic testing without
informed consent; prohibits the use of genetic test results to
affect the terms, conditions, and privileges of employment; and
prohibits payments of benefits to employees in return for tak-
ing a genetic test. As with most state legislation addressing
health insurance and genetic discrimination, these laws also
tend to focus narrowly on the genetic test.'' These laws do
not prohibit employers from requiring a general medical re-
lease. At least one state law appears to allow for genetic test-
ing without informed consent where it is shown to be directly
related to the occupational environment.0 Since most em-
ployers will continue to have access to genetic information, the
burden will be on the employee to prove that the employer
used genetic information to discriminate in the workplace.
VI. PRIVACY AND CONFIDENTIALITY OF
GENETIC INFORMATION
The privacy and confidentiality of genetic information is
at issue in a number of contexts. Once again, there is no feder-
al law that specifically addresses genetic privacy and confiden-
tiality. There is currently a patchwork of legislative sources
that addresses, to varying degrees, genetic privacy and confi-
dentiality. These include medical records confidentiality stat-
utes, public health data bases and registries, public health ge-
netic programs, research regulations, DNA databanks, and anti-
discrimination statutes. Most of these statutes provide for ex-
ceptions to confidentiality protections for criminal investiga-
tions, parentage, and adoption.
Recently enacted state laws to prevent genetic discrimina-
99. See OR. REv. STAT. § 659.036 (1995).
100. See S.B. 695,207th Leg., 1st Ann. Sess. (NJ. 1996) (enacted). This is a comprehensive
statute that includes provisions for employment, housing, banking, privacy, health, life, and
disability insurance. Id.
101. The recently enacted New Jersey statute, in fact, does provide broader protection
against the use of genetic information. Id.
102. See, e.g., A.B. 7839,219th Gen. Assembly, 2d. Reg. Sess. § 5 (N.Y. 1996) (enacted).
103. See Lawrence 0. Gostin, Genetic Privacy, 23 J. LAW, MED. & ETHICS 320,326 (1995)
(discussing the genetic information infrastructure and how the privacy of genetic information is
addressed in the scientific community and through state statutes).
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tion in health insurance integrate some strong privacy protec-
tion."' As noted earlier, the Wisconsin law established that
insurers may not "require or request directly or indirectly any
individual to reveal whether the individual or a member of the
individual's family has obtained a genetic test or what the
results of the test, if obtained by the individual or a member of
the individual's family, were."' 5 Many of the other state
laws and pending bills have also adopted this provision.16
Ironically, a recent Wisconsin bill that would have expanded
the definition of genetic test, deleted this provision." 7 Propo-
nents of the bill believed that as long as state law prohibits the
use of genetic information in the underwriting process, there
may be legitimate reasons for health insurers to otherwise
require or request genetic information.0 8 For example, they
argued that health maintenance organizations, which are both
insurers and health care providers, may need this information
to treat the patient and insurers may need access to this infor-
mation to verify claims."
Other states have further expanded on protecting the dis-
closure of genetic information. California, for example, prohib-
its disclosure of genetic test results to any third party without
written authorization."0 Written authorization is required for
each separate disclosure of genetic test results and shall specify
the person or entity to whom the disclosure will be made.
Negligent and willful disclosure without authorization are sub-
ject to both civil and criminal liability."' Colorado specif-
ically provides that information obtained from genetic testing
104. See Rothenberg, supra note 48, at 314-17.
105. Wisc. STAT. ANN. § 631.89(2)(b) (West 1996).
106. See Rothenberg, supra note 48, at 314-16.
107. A.B. 227, 92d Leg., Reg. Sess. § 10 (Wis. 1995) (amending existing Wisconsin law to
allow insurers to require or request that an individual or an individual's family member obtain a
genetic test or reveal whether such test has been obtained and the results).
108. See SPECIAL COMM. ON GENETIC & MED. INFO., Wis. JOINT LEGISLATIVE COUNCIL,
LEGISLATION ON GENETIC & MED. INFO., A, B,93-19 (1994) (discussing Assembly Bill 1265 and
its listing of circumstances under which patient health care records can be released upon request
without informed consent, including release to a health care provider rendering assistance to the
patient).
109. Id.
110. CAL. INS. CODE § 10149.1 (Deering 1996).
111. Id.
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shall be "confidential and privileged,""' 2 and Oregon and
Georgia establish that genetic information is the "property of
the individual."' 13 Nevertheless, Oregon and Georgia both
provide, as do a number of the other states, for specific excep-
tions in which written authorization is not required for disclo-
sure (i.e., paternity, criminal proceedings, health department
protocols). Even when these statutes require informed consent
prior to genetic testing, they do not address whether the in-
formed consent process will incorporate a warning that the test
results may be disclosed without authorization under certain
circumstances.
Additionally, a Florida law passed in 1992 permits DNA
analysis to be used in criminal prosecutions, other criminal
matters, and paternity determinations without informed con-
sent."4 Except in these circumstances, the statute declares
that the test results are the exclusive property of the person
tested, are confidential, and may not be disclosed without con-
sent."5 Nevertheless, the statute does not prohibit the use of
genetic information in determining health insurance coverage
and benefits. If DNA test results are used in any decision to
grant or deny insurance, the individual must be notified and the
analysis must be repeated to verify its accuracy.
Some statutes address privacy issues created by the access
to shared insurance databases. The Wisconsin"1 6 and New
Hampshire"' laws provide that insurers writing life and dis-
ability income insurance, in addition to health insurance, can-
not use genetic test information when underwriting their health
insurance policies. In Minnesota, where a life insurance compa-
ny may require a genetic test, the statute provides that written
informed consent must include information on the uses and
limitations of the test, as well as the individual's right to confi-
dential treatment of the information." 8 It is worth noting that
112. COLO. REv. STAT. § 10-3-1104.7(3)(a) (1996).
113. S.B. 276,68th Or. Leg. Ass., Reg. Sess. (1995) (enacted); GA. CODE ANN. § 33-54-1(1)
(1996).
114. FLA. STAT. ANN. § 760.40(2)(a) (West 1995).
115. Id.
116. Wisc. STAT. ANN. 631.89(3)(b) (West 1996).
117. N.H. REV. STAT. ANN. § 141 -H:4, 5 (1995).
118. MINN. STAT. § 72A.139(S) (1995).
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the statute specifically provides that "[i]f the individual tested
has not given written consent authorizing a physician to receive
the test results, the individual must be urged, at the time that
the individual is informed of the genetic test results .. to
contact a genetic counselor or other health care profession-
al. ,," 19
As noted earlier, currently there is no federal law specifi-
cally addressing genetic privacy. It is critical that any federal
legislation that regulates genetic (and medical) privacy not
preempt stricter protections integrated into state anti-discrimi-
nation statutes. Furthermore, medical privacy legislation must
specifically address protections of genetic information. Current-
ly, federal proposals are pending that vary with respect to how
they address these issues. 2 '
VII. RIGHTS AND RESPONSIBILITIES WITHIN
THE FAMILY
Concerns over privacy and confidentiality extend beyond
the employment and insurance context. For many individuals,
the primary concern may be for privacy in the context of fami-
ly, including the extended family. This is an area where it may
be inappropriate for the law to have any meaningful role. Me-
diating roles based primarily on blood, rather than on family
relationships, will create new challenges. In the Orthodox Jew-
ish community, there is fear that genetic testing without clear
medical benefit will only cause harm to individuals, threaten
the privacy of families, and even hamper the prospects of
marriage. A Jewish Community Relations Council official
queried, "If you know that someone in the family has a specif-
ic predisposition to BRCA1, what does this do [to] their possi-
ble matches?"' 2
Traditional medical ethics may have to be re-examined to
119. MINN. STAT. §72A.139(6) (1995). Similar provisions are included in the California
statute. See CAL. INS. CODE § 10148(a)-(b) (Deering 1996).
120. See S. 1360, 104th Cong. (1995) (proposing a bill entitled the "Medical Records
Confidentiality Act of 1995"); S. 1898, 104th Cong. (1996) (proposing a bill entitled the "Genetic
Confidentiality and Nondiscrimination Act of 1996"); H.R. 3482, 104th Cong. (1996) (proposing
a bill entitled the "Medical Privacy in the Age of Technologies Act of 1996").
121. Doc Wants New Study of Jewish Cancer Gene, supra note 44, at 6.
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accommodate changing fights and responsibilities within the
family. The paradigm of individual autonomy in health care
supports an individual's right to evaluate the benefits and risks
of testing, to decide whether to be tested, and whether to share
test results. However, in the context of genetics, what is the re-
sponsibility of the individual and the provider to share test
results with other family members? 2 Is the patient, in fact,
the individual, or the family unit? When sharing information,
how many generations should be included? Should a
communitarian ethic of sharing be integrated into the ethical
paradigm? What responsibilities will there be to obtain and
share information about genetic predispositions to cancer? In
certain cases, the mutation cannot be found without testing the
affected carrier and other blood relatives. What if some rela-
tives want to be tested and some do not? Can family members
keep genetic secrets? When should the researcher or physician
intervene to encourage family members to participate in test-
ing? Who in the family should contact family members with
genetic information? Although there is no ethical consensus or
clear legal precedent in genetics,"a3 in the context of HIV and
communicable diseases, some conclude that one might have an
ethical and legal duty to share information about contagious
diseases.'24 The rationale, in part, for the duty is to prevent
122. See, e.g., Madison Powers, Privacy and the Control of Genetic Information, in THE
GENETIC FROmnER: ETHICS, LAW, AND PoLIcY 77, 92-95 (Mark S. Frankel & Albert H. Teich
eds., 1994) (discussing when genetic information should be disclosed to third parties in order to
protect them from harm); Sonia M. Suter, Whose Genes are These Anyway? Familial Conflicts
OverAccess to Genetic Information, 91 MICH. L. REv. 1854, 1854 (1993) (arguing that courts and
legislatures should not follow a presumption against mandating disclosure of a person's genetic
information to third parties).
123. See, e.g., Ruth Macklin, Privacy and Control of Genetic Information, in GENE
MAPPING: USING LAW AND ETHICS AS GUIDES 157, 158 (George Annas & Sherman Elias eds.,
1992) (discussing the concept of privacy and its implication for the confidentiality of genetic
information); Mary Z. Pelias, Duty to Disclose in Medical Genetics: A Legal Perspective 39 AM.
J. MED. GENETICS 347, 349-52 (1991) (discussing the duty of medical geneticists to disclose
medical and genetic information in light of the lack of legal precedent governing a physician's
duty to disclose).
124. See, e.g., Kenneth E. Labowitz, Beyond Tarasoff AIDS and the Obligation to Breach
Confidentiality 9 ST. LOUISE U. PUB. L. REv. 495, 512 (1990) (discussing the medical
profession's standard for third party notification concerning a patient who has a positive HIV
status and the mandates of the Public Health Service and Center for Disease Control). But see,
e.g., Karen H. Rothenberg & Stephen J. Paskey, The Risk of Domestic Violence and Women with
HIV Infection: Implications for Partner Notification, Public Policy, and the Law, 85 AM. J. PUB.
HEALTH 1569, 1569 (1995) (exploring implications of the partner notification strategy in the fight
against AIDS in the context of domestic violence).
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the spread of disease. Such an analogy may be premature and/-
or ill-advised in the context of predictive genetic testing for
cancer.
Two recent cases have considered the physician's duty to
warn relatives that they are at risk of developing a genetic
disease. In Pate v. Threlkel,'" the Florida Supreme Court
analyzed the duty to warn the patient of "genetic transferabili-
ty" and the role of family members in sharing genetic informa-
tion."6 In this case, a patient's adult child brought a medical
malpractice action based on the physicians' failure to warn the
patient that her condition, medullary thyroid carcinoma, was
genetically transferable and that her adult children should be
tested for the condition. 7 The court held that expert testi-
mony by physicians would determine the standard of care and
thereby whether the physicians had a duty to warn under the
circumstances. Obviously, this case demonstrates the impor-
tance of risk assessment, an understanding of cancer genetics,
and the need for providers to take the lead, rather than the
courts, in establishing the standard of care for genetic testing.
The court also "emphasized" that in any circumstances in
which the physician has a duty to war of a genetically trans-
ferable disease, that duty will be satisfied by warning the pa-
tient. ' The court clarified that the physician has no duty to
warn various members of the patient's family, reasoning that it
would be prohibited by disclosure laws, as well as be impracti-
cal, difficult, and "place too heavy a burden on the physi-
cian. ' Rather, the court reasoned that the "patient ordinari-
ly can be expected to pass on the warning"'"3 to family mem-
bers.
More recently, the New Jersey Superior Court, in Safer v.
Pack, '' further expanded on the Pate opinion. In Safer, the
plaintiff, who was diagnosed with a form of colon cancer, sued
the estate of the physician who had first treated her father for
125. 661 So.2d 278 (Fla. 1995).
126. Id. at 280-82.
127. See id. at 278-79.
128. Id. at 282.
129. Id.
130. Id.
131. 677A.2d 1188 (NJ. 1996).
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the same disease over forty years earlier. She argued that the
physician had a duty to inform the family that they were poten-
tially at risk of developing this genetically transmissible condi-
tion. On appeal from the trial court's dismissal of her com-
plaint, the Superior Court held that the physician did have a
duty to wam and declined to hold as in Pate "that in all cir-
cumstances, the duty to warn will be satisfied by informing the
patient."' It predicted that as the issues develop at trial, the
court may have "to resolve a conflict between the physician's
broader duty to warn and his fidelity to an expressed prefer-
ence of the patient that nothing be said to family members
about the details of the disease."'33 These two cases further
highlight our need for better understanding family relation-
ships, privacy and confidentiality concerns, and realistic expec-
tations in the genetics context.
In light of these developments, it may be even more criti-
cal to recognize the implications of testing children for cancer
susceptibility. 4 When, if at all, do you tell the child of their
carrier status? Is it realistic to have a parent withhold such
information from a child? If not, when is the right age to share
this information? Considering the social and psychological
risks associated with testing, it may only be appropriate for the
child to make the decision to undergo testing when they reach
maturity.'35 If the testing of a child has a medical benefit that
cannot be postponed until adulthood, it might be ethical to
132. Id. at 1192.
133. Id.
134. See generally Board of Directors, Am. Soc'y of Hum. Genetics & Board of Directors,
Am. C. of Medic. Genetics, Points to Consider: Ethical, Legal and Psychosocial Implications of
Genetic Testing in Children and Adolescents, 57 AM. J. HUM. GENETICs 1233, 1234 (1995)
(recommending that providers engage families in comprehensive discussions of genetic testing
issues and provide them with specific information about testing) [hereinafter Am. Soc'y of Hum.
Genetics & Am. C. of Medic. Genetics]; Ellen Wright Clayton, Removing the Shadow of the Law
from the Debate about Genetic Testing of Children, 57 AM. J. MED. GENETICS 630, 630 (1995)
(arguing that tort and constitutional law in the United States have limited impact in the debate
over genetic testing of children); Diane E. Hoffmann & Eric A. Wulfsberg, Testing Children for
Genetic Predispositions: Is it in Their Best Interest?, 23 J. L. MED. & ETHIC 331, 331 (1995)
(exploring the psychological impact, burdens, benefits, and other issues associated with testing
children for genetic predispositions); Dorothy C. Wertz et al., Genetic Testing for Children and
Adolescents: Who Decides?, 272 JAMA 875, 875 (1994) (discussing the ethical, legal, and
psychological implications of presymptomatic testing of children).
135. See Am. Soc'y of Hum. Genetics & Am. C. of Med. Genetics, supra note 134, at 1238.
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offer testing.'36 Because of concerns for psychological risk,
stigma, and discrimination, parental anxiety alone should not
be a justification for predictive testing of children. 3 7 The Na-
tional Action Plan on Breast Cancer states that "[ulnless a
benefit for medical interventions in childhood can be demon-
strated, which is currently not the case for heritable breast and
ovarian cancer, testing on individuals younger than eighteen
years should not be undertaken."'38
Reproductive decisionmaking in the genetic context also
presents new and related challenges. In the near future,
preimplantation diagnosis and assisted reproductive technolo-
gies may provide the wealthy with the option of the selective
implantation of embryos with normal BRCA1 genes. More
generally, if genetic testing for cancer susceptibility is market-
ed to the general population, it may be targeted at pregnant
women. A recent article in Obstetrics and Gynecology"9 pre-
dicted that there would be increasing demand for prenatal
testing for mutations in the BRCA1 gen," In fact, most ge-
netic testing is done on pregnant women 4' and predictive
testing for cancer may be no exception.
More specifically, it is reasonable to predict that Jewish
pregnant women will be the first group targeted since Jews are
already being screened for other "Jewish" genetic disorders and
are being recruited for 185delAG testing. 42 More generally,
with knowledge of the mutation in the parent, prenatal testing
using fetal cells will be relatively easy and quick, allowing for
pregnancy termination. 43 Will only female fetuses be tested
and aborted? Is it ethical to abort for an adult onset disease in
which we still understand so little about penetrance and the
136. See id. at 1234.
137. See id. at 1238.
138. National Action Plan on Breast Cancer, Position Paper, Commentary on the ASCO
Statement on Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL ONCOLOGY 1738, 1739
(1996).
139. Johnathan M. Lancaster et al., An Inevitable Dilemma: Prenatal Testing for Mutations
in the BRCA1 Breast-Ovarian Cancer Susceptibility Gene, 87 OBSTETRICS & GYNECOLOGY 306,
306(1996).
140. Id. at 307.
141. See, e.g., WOMEN AND PRENATAL TESTING: FACING THE CHALLENGES OF GENETIC
TECHNOLOGY (Karen H. Rothenberg & Elizabeth J. Thomson eds., 1994).
142. See Genetics & IVF Institute, supra note 24.
143. See Lancaster et al., supra note 139, at 307.
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phenotypic effects of different mutations?'" Once the test is
offered, we cannot place legal limits on termination options.
Yet, if a woman decides not to abort, what implications does
this have for the child's rights? We are in fact testing minors
without their consent. The National Action Plan on Breast
Cancer has determined that "[a] host of moral and ethical is-
sues make it inappropriate to offer testing for breast and ovari-
an cancer susceptibility as part of prenatal diagnosis."'45
VIII. CONCLUSION: UNANSWERED QUESTIONS
Predictive genetic testing for breast cancer raises a number
of complex ethical, legal, and social challenges. Perhaps our
greatest public policy challenge will be to determine when, if
at all, it will be appropriate to make the transition from predic-
tive testing for high-risk individuals and families in a research
context to testing the general population for cancer risk. Will
the commercial market promote testing for the general popula-
tion before we have been able to carry out the benefit/risk
analysis even in the high risk population?'" As the flow of
genetic information increases, so too will the risk of its misuse.
Should testing be restricted until we enact anti-discrimination
144. See id. at 307.
145. See National Action Plan on Breast Cancer, supra note 138, at 1739.
146. See generally American Society of Clinical Oncology, Statement of the American
Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL
ONCOLOGY 1730, 1730-36 (1996) (stating that any physician who offers genetic testing should be
aware of, and be able to communicate, the benefits and limits of current testing procedures, and
the range of treatment options available to patients and their families); National Action Plan on
Breast Cancer, supra note 138, at 1739 (stating that testing should only be done under institutional
review board approved research studies); Frances M. Visco, National Breast Cancer Coalition,
Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL
ONCOLOGY 1737, 1737 (1996) (stating the National Breast Cancer Coalition's concern about the
need for more research as well as the lack of legislation prohibiting the misuse of genetic
information); National Advisory Council for Human Genome Research, Nat'l. Inst. of Health,
Statement on Use of DNA Testing for Presymptomatic Identification of Cancer Risk, 271 JAMA
785, 785 (1994) (discussing issues which must be addressed before widespread use of DNA
testing for a predisposition to cancer can be recommended); Ad Hoc Committee on Breast and
Ovarian Cancer Screening, Am. Soc. of Hum. Genetics, Statement of the American Society of
Human Genetics on Genetic Testing for Breast and Ovarian Cancer Predisposition, 55 AM. J.
HUM. GEt nCs i (1994) (identifying characteristics and prerequisites for testing for the BRCA1
cancer gene in high risk and general population groups).
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and genetic privacy legislation nationwide? Should the com-
mercial market be regulated? How can we explain relative and
absolute risks to the general public? How can we explain the
limitations of testing technology? How can we assure quality
control over the testing process? What implications will testing
have, for example, on cancer surveillance and prevention strat-
egies within our current healthcare system? How will individu-
als be able to integrate predictive testing results with health
behavior, lifestyle, and environmental factors that may signifi-
cantly contribute to cancer morbidity and mortality? How can
the FDA and other regulatory agencies assure the public that
predictive genetic testing has clinical and analytical validi-
ty? 47 These questions have no simple answers.
Thus, until we have a better understanding of the benefits
and risks of genetic testing and our strategies for how best to
proceed in order to protect the public, we must strive to resist
a genetic "quick fix" mentality that promotes genetic testing in
the healthcare market. Obviously, there is no "quick fix" for
the ethical, legal, and social challenges.
147. See Technological Advances in Genetic Testing: Implications for the Future, 104th
Cong. 75-86 (1996) (statement of Karen H. Rothenberg).
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